New combo therapy aims to tame bone marrow cancer

NCT ID NCT06773195

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study tests whether adding ulixertinib to the standard drug ruxolitinib is safe and helpful for people with myelofibrosis, a type of bone marrow cancer. About 37 adults who are already on a stable dose of ruxolitinib will receive different doses of ulixertinib. The goal is to find the best dose with few side effects and see if the combination improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib and ulixertinib
What this could lead to: If successful, this could point toward a new combination treatment that better controls myelofibrosis symptoms and progression.
What could go wrong: This is an early phase 1/2 trial with only 37 participants, so safety and effectiveness are not yet proven. Side effects from the drug combination may occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cellular phase chronic idiopathic myelofibrosis myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS

Contacts and locations

Locations

Cleveland Clinic
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States
Massachusetts General Hospital (Data Collection Only)
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.